Albany, NY -- (ReleaseWire) -- 05/13/2014 -- Histone deacetylase (HDAC) are enzymes which remove acetyl groups from an N-acetyl lysine amino acid present on a histone, thus wrapping the DNA tightly by the histones. Histone deacetylase inhibitors (HDIs) are compounds which interfere with this function of histone deacetylase. HDIs display promising potential in oncology for applications such as diagnosis, cancer detection and prognosis. HDIs are emerging class of oncology therapeutics for the treatment of solid and hematological malignancies. Based on the classes, histone deacetylase are classified into class 1, class 2 and class 3 HDAC. HDAC inhibitors leads to accumulation of acetylated nuclear histones in both tumor and normal tissues, providing an alternate marker for the biological activity of HDAC inhibitors. Inhibition of HDAC also results in acetylation transcription factors such as GATA-1, p53 and estrogen receptor-alpha. HDIs are potent anti-proliferative agents with moderately little effect on normal tissues.
Browse Full Report with TOC: http://www.transparencymarketresearch.com/histone-deacetylase-inhibitors.html
Based on applications, histone deacetylase inhibitors are categorized into oncology, neurology and others diseases. Presently there are four approved HDI products in the market namely Vorinostat (Zolinza), Romidepsin (Istodax), Vidaza and Dacogen. Consequently, global biopharmaceutical companies are conducting research for its application in different indications.
North America leads the histone deacetylase inhibitors market with rapid acceptance of these products in this region. Globally, this market would be growing at a very rapid pace owing to a tremendous potential of this class of drugs in oncology therapy. Rising incidence of oncology and aging population would be the driving factors for this market.
Some of the key players in this market include Merck & Co., Inc., Celgene Corporation, Eisai Pharmaceuticals, Novartis, Acetylon Pharmaceuticals, Celleron Therapeutics, Envivo Pharmaceuticals and Pfizer, Inc. These companies are aiming to discover new products in this class, through prospective pipeline, collaborations and ventures.
This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
- North America
- Asia Pacific
- Rest of the World
This report provides comprehensive analysis of
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
Read More Reports on Pharmaceutical Markets: http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html
About Transparency Market Research
Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.
TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources along with various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information which is indispensable for businesses to sustain their competitive edge.
Enquiry before Buying @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1927
90 State Street,
Albany NY - 12207
Browse Market Research Blogs: